Veeva Systems Inc. (VEEV) $190.12
Veeva Systems surged 16% in the last month, but the technicals warn that this rally has overextended the stock.
52-wk High $310.5
📌 Investment Snapshot
- Price: $190.12 (P/E 33.6x)
- Revenue: $883M (Q1 2026)
- Catalyst: Strong institutional inflow
- Target: $244.59 (+28.6% upside)
The stock trades in overbought territory with an RSI of 84.5. Wait for a pullback to key support levels before initiating new positions.
| 📍 Entry Zone | $169.63 or below | 🛑 Stop-Loss | $156.00 |
| 📋 Adjust If | The stock breaks above $202 with sustained volume. | ||
The Investment Case — Why Now?
Veeva maintains dominance in life sciences cloud infrastructure, yet the rapid ascent leaves little room for error. Investors should recognize that the current momentum outpaces the underlying fundamental narrative.
Valuation remains the primary hurdle, as the 33.6x P/E multiple leaves the stock exposed to any macro-driven volatility. Can the company justify this premium if the 10Y Treasury yield pushes higher?
🤔 Does the current 16% monthly gain reflect genuine business improvement or simply speculative momentum?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Health Information Services |
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $156.22 on 2026-06-22
The stock trades above the SMA50 ($168.53), confirming a strong uptrend, yet the distance from the SMA200 ($211.19) suggests a potential mean reversion.
RSI 84.5 screams overbought, while the MACD at 6.95 confirms the bullish trend but warns of exhaustion.
Volume Profile points to $169.63 as the Point of Control, marking a logical re-entry zone during a pullback.
Liquidity sweeps at $156.22 and $156.69 highlight institutional defense, providing a floor for future dips.
The recent bearish FVG fill at $190.09-$191.38 suggests sellers remain active at these levels, capping immediate upside.
🤔 Would you add to your position here, or wait for a test of the $169.63 POC?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| VEEV | Veeva Systems | 33.6x |
| SPY | S&P 500 | 22.1x |
| CRM | Salesforce | 45.2x |
| ORCL | Oracle | 28.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $883M | $1.57 | +11% |
| Q4 2025 | $836M | $1.44 | +9% |
| Q3 2025 | $811M | $1.44 | +8% |
| Q2 2025 | $789M | $1.19 | +7% |
Free cash flow remains robust at $1.1B, supporting ongoing buybacks.
Revenue growth shows consistent acceleration, though the market has priced in much of this success.
🚀 Growth Drivers — What Moves the Stock
- Cloud Expansion 🟡 Priced In — Continued adoption of Veeva Vault across global life sciences firms.
- AI Integration 🟢 Upside Surprise — New AI-driven analytics tools enhance customer retention.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 11,558 |
| Vanguard Portfolio Management | 7,376 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| Thomas D. Schwenger | President | 2026-07-01 | Sale | 2907 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 5.0% | 2.5 |
⚠ Key Risk Factors
~$2B impact
~$500M impact
🤔 Do you view the recent insider sales as a signal of local tops or routine portfolio rebalancing?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $350.00 | $244.59 | $165.00 | 27 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Goldman Sachs | Sell | $190.00 | 2026-06-04 | Maintained |
| Stifel | Buy | $280.00 | 2026-06-04 | Maintained |
Analysts remain broadly bullish, yet the dispersion between $165 and $350 highlights significant uncertainty.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Strong recurring revenue model
- High switching costs for clients
📊 Base Case
The company continues to execute, but the stock needs to consolidate gains.
🐻 Bear Case
- Valuation premium unjustified
- Macro headwinds impacting IT spend
🎯 Investor Action Plan — By Profile
Avoid new longs until RSI cools below 60.
Wait for a pullback to the $169 POC level.
Maintain existing core positions but avoid adding at these levels.
❓ Investor FAQ — People Also Ask
Q: Why is the verdict WAIT despite the strong uptrend?
The RSI of 84.5 indicates the stock is severely overbought and due for a technical correction.
Q: What is the key support level to watch?
The Point of Control (POC) at $169.63 serves as the primary area of institutional interest.
Q: Are insiders buying or selling?
Recent filings show several executives, including President Thomas Schwenger, selling shares in early July.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to verify if this analysis still holds?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. All investments carry risk.
All active positions and their real-time performance are tracked on our Investment Log.
#VEEV #VeevaSystems #StockMarket #Healthcare #Investing #TechnicalAnalysis #GoldmanSachs #WallStreet